Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Prize winner
Published by: Harvard Business Publishing
Originally published in: 2002
Version: 30 November 2005
Length: 24 pages
Data source: Published sources

Abstract

In the final years of the 20th century, the world was hit by a plague of epidemic proportions - AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a combination of education, prevention, and cutting-edge medicines. But in the developing world, where health care expenditures were often paltry, AIDS continued to rampage. By the year 2000, 25 million people in Africa alone were infected with the disease. Millions had already died. Nearly all of the medicines that treated AIDS had been developed - at great expense - by the major western pharmaceutical firms. These medicines were expensive to produce and often difficult to administer. They demanded levels of income and structures of distribution that often were sorely lacking in the developing world. Increasingly, activist groups were demanding that the pharmaceutical companies respond to the AIDS epidemic with drastic measures, giving their drugs away for free or abandoning the patent rights that had long protected their intellectual property. The pharmaceutical firms needed to respond to their critics. The question was, how?
Location:
Industry:
Other setting(s):
1996-2002

About

Abstract

In the final years of the 20th century, the world was hit by a plague of epidemic proportions - AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a combination of education, prevention, and cutting-edge medicines. But in the developing world, where health care expenditures were often paltry, AIDS continued to rampage. By the year 2000, 25 million people in Africa alone were infected with the disease. Millions had already died. Nearly all of the medicines that treated AIDS had been developed - at great expense - by the major western pharmaceutical firms. These medicines were expensive to produce and often difficult to administer. They demanded levels of income and structures of distribution that often were sorely lacking in the developing world. Increasingly, activist groups were demanding that the pharmaceutical companies respond to the AIDS epidemic with drastic measures, giving their drugs away for free or abandoning the patent rights that had long protected their intellectual property. The pharmaceutical firms needed to respond to their critics. The question was, how?

Settings

Location:
Industry:
Other setting(s):
1996-2002

Related


Awards, prizes & competitions